Anti‐chromatin and anti‐C1q antibodies in systemic lupus erythematosus compared to other systemic autoimmune diseases

References

• Huong D. L., Papo T., Beaufils H., Wechsler B., Bletry O., Baumelou A., et al. Renal involvement in systemic lupus erythematosus. A study of 180 patients from a single center. Medicine (Baltimore) 1999; 78: 148–66
   PubMed Web of Science ®Google Scholar
• Hahn B. H. Antibodies to DNA. N Engl J Med 1998; 338: 1359–68
   PubMed Web of Science ®Google Scholar
• Seelen M. A., Trouw L. A., Daha M. R. Diagnostic and prognostic significance of anti‐C1q antibodies in systemic lupus erythematosus. Curr Opin Nephrol Hypertens 2003; 12: 619–24
   PubMed Web of Science ®Google Scholar
• Coremans I. E., Spronk P. E., Bootsma H., Daha M. R., van der Voort E. A., Kater L., et al. Changes in antibodies to C1q predict renal relapses in SLE. Am J Kidney Dis 1995; 26: 595–601
   PubMed Web of Science ®Google Scholar
• Siegert C. E., Daha M. R., Tseng C. M., Coremans I. E., van Es L. A., Breedveld F. C. Predictive value of IgG autoantibodies against C1q for nephritis in SLE. Ann Rheum Dis 1993; 52: 851–6
   PubMed Web of Science ®Google Scholar
• Trendelenburg M., Marfurt J., Gerber I., Tyndall A., Schifferli J. Lack of occurrence of severe lupus nephritis among anti‐C1q autoantibody‐negative patients. Arthritis Rheum 1999; 42: 187–8
   PubMed Web of Science ®Google Scholar
• Amoura Z., Koutouzov S., Chabre H., Cacoub P., Amoura I., Musset L., et al. Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases: antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. Arthritis Rheum 2000; 43: 76–84
   PubMed Web of Science ®Google Scholar
• Cairns A. P., McMillan S. A., Crockard A. D., Meenagh G. K., Duffy E. M., Armstrong D. J., et al. Antinucleosome antibodies in the diagnosis of systemic lupus erythematosus. Ann Rheum Dis 2003; 62: 272–3
   PubMedGoogle Scholar
• Cervera R., Vinas O., Ramos‐Casals M., Font J., Garcia‐Carrasco M., Sisó A., et al. Anti‐chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy. Ann Rheum Dis 2003; 62: 431–4
   PubMed Web of Science ®Google Scholar
• Li C. H., Li Y. C., Xu P. S., Hu X., Wang C. Y., Zou G. L. Clinical significance of anti‐glomerular basement membrane antibodies in a cohort of Chinese patients with lupus nephritis. Scand J Rheumatol 2006; 35: 201–8
   PubMed Web of Science ®Google Scholar
• Tan E. M., Cohen A. S., Fries J. F., Masi At., McShane D. J., Rothfield N. F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–7
   PubMed Web of Science ®Google Scholar
• Hochberg M. C. Updating the American College of Rheumatology revised criteria for the classification of SLE. Arthritis Rheum 1997; 40: 1725
   PubMed Web of Science ®Google Scholar
• Gourley M. F., Austin H. A., Scott D., Yarboro C. H., Vaughan E. M., Muir J., et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. Ann Intern Med 1996; 125: 549–57
   PubMed Web of Science ®Google Scholar
• Bombardier C., Gladman D. D., Urowitz M. B., Caron D., Chan C. H. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630–40
   PubMed Web of Science ®Google Scholar
• Weening J. J., D'Agati V. D., Schwartz M. M., Seshan S. V., Alpers C. E., Appel G. B., et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65: 521–30
   PubMed Web of Science ®Google Scholar
• Leavitt R. Y., Fauci A. S., Bloch D. A., Michel B. A., Hunder G. G., Arend W. P., et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990; 33: 1101–7
   PubMed Web of Science ®Google Scholar
• Jennette J. C., Falk R. J., Andrassy K., Bacon P. A., Churg J., Gross W. L., et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187–92
   PubMed Web of Science ®Google Scholar
• Vitali C., Bombardieri S., Jonsson R., Moutsopoulos H. M., Alexander E. L., Carsons S. E., et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American–European Consensus Group. Ann Rheum Dis 2002; 61: 554–8
   PubMed Web of Science ®Google Scholar
• Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581–90
   PubMed Web of Science ®Google Scholar
• Burlingame R. W., Boey M. L., Starkebaum G., Rubin R. L. The central role of chromatin in the autoimmune responses to histones and DNA in systemic lupus erythematosus. J Clin Invest 1994; 94: 184–92
   PubMed Web of Science ®Google Scholar
• Fiehn C., Hajjar Y., Mueller K., Waldherr R., Ho A. D., Andrassy K. Improved clinical outcome of lupus nephritis during the last decade. The importance of early diagnosis and treatment. Ann Rheum Dis 2003; 62: 435–9
   PubMed Web of Science ®Google Scholar
• Trendelenburg M., Lopez‐Trascasa M., Potlukova E., Moll S., Regenass S., Frémeaux‐Bacchi V., et al. High prevalence of anti‐C1q antibodies in biopsy proven active lupus nephritis. Nephrol Dial Transplant 2006; 21: 3115–21
   PubMed Web of Science ®Google Scholar
• Chabre H., Amoura Z., Piette J. C., Godeau P., Bach J. F., Koutouzov S. Presence of nucleosome‐restricted antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1995; 38: 1485–91
   PubMedGoogle Scholar